Oklahoma Chapter of the American College of Physicians Virtual Meeting 2020

Permanent URI for this collection

https://hdl.handle.net/11244/325646

Browse

Browsing Oklahoma Chapter of the American College of Physicians Virtual Meeting 2020 by Author "Bader, Nimrah"

Filter results by typing the first few letters
Now showing 1 - 2 of 2
  • Thumbnail Image
    ItemOpen Access
    Factors Associated with the Maintenance of Colonic Insufflation During Colonoscopy
    (2020-10) Bader, Nimrah; Yohannan, Bryce; Corredine, Thomas; Madhoun, Mohammad
    Colonoscopy is a diagnostic and therapeutic procedure performed for several indications including colorectal cancer (CRC) screening, adenoma surveillance, and investigation of gastrointestinal symptoms. Insufflation of the colon with gas allows for adequate visualization of the mucosal tissue and advancement of the endoscope; however, it can cause pain and discomfort. Thus, the majority of colonoscopies are performed with sedation in order to mitigate discomfort and enhance the colonoscopy experience for both the patient and the endoscopist. We hypothesized that deeper levels of sedation would lead to more difficulty in maintaining insufflation. We aimed to evaluate factors associated with difficulty maintaining insufflation. Methods: We performed a prospective study of all patients who underwent outpatient colonoscopies at the Veteran Affairs Medical Center in Oklahoma City between November 2019 and March 2020. Colonoscopies were performed by gastroenterology fellows and attending gastroenterologists. Indications for colonoscopies were CRC screening, positive fecal immunochemical test, symptomatic, and adenoma surveillance. Procedures were done under Monitored Anesthesia Care (MAC) with propofol or moderate sedation with fentanyl, midazolam, and diphenhydramine. Insufflation was done with carbon dioxide. Data collection involved two parts. Firstly, baseline demographic information was obtained from the electronic medical record (EMR) along with colonoscopy details including type and doses of sedatives; total number of polyps, size of polyps, and specific location in colon; and total procedure times including insertion and withdrawal. Secondly, a post-procedure questionnaire was completed by the endoscopists and recorded the bubble score, endoscopic maneuvers, and difficulty maintaining insufflation. Results: A total of 542 participants underwent colonoscopies during this period. Twelve participants were excluded from the study and 37 participants did not have completed questionnaires. We found that difficulty maintaining insufflation was reported in 129 (26%) participants compared to 364 participants where no difficulty was reported. Multivariate analysis showed that patients who had difficulty maintaining insufflation were more likely to be of an older age (P=0.003), had undergone MAC sedation (P=<0.0001), were more likely to have longer procedure times (P=.0025) and fellow involvement (P=0.0002) with the procedure. Discussion: We observed that difficulty in maintaining insufflation during colonoscopy was reported in over one-quarter of the colonoscopies done. We found four factors associated with difficulty maintaining insufflation: use of propofol sedation, older age, fellow involvement, and longer procedural times. We could not find literature that explored maintenance of insufflation. Further investigation into these factors and their relationship with maintaining insufflation is warranted as this may improve the colonoscopy experience.
  • Thumbnail Image
    ItemOpen Access
    Name the Syndrome: Cytokine Release Syndrome or Toxic Shock Syndrome in a Patient on Avelumab for Ependymal Tumor
    (2020-10) Bader, Nimrah; Ul-Haq, Aejaz
    Introduction: The use of immune checkpoint inhibitors (ICIs) has dramatically changed the outlook of cancer therapy. As a result, their use is becoming prevalent and a more diverse range of clinicians will encounter patients on immunotherapy and their immune-related adverse events (irAEs). Our objective is to describe a case of suspected cytokine release storm in a patient enrolled in a phase I trial on combination therapy with PDL1 inhibitor Avelumab and oral DNA PK inhibitor who was initially treated as toxic shock syndrome. Case: A 38 year-old-woman with an ependymal tumor on a phase I trial with PDL1 Inhibitor Avelumab and oral DNA PK inhibitor presented with fever and rash a few hours after receiving Avelumab infusion. On exam, vitals were Temperature 39.2 C, HR 148, BP 87/45, RR 30, Pulse Ox 98% on ambient air. Examination was significant for an alert and conversant woman with macular erythema which involved the face, upper extremities, chest, and thighs. Indwelling lines were noted: a peritoneal catheter and a PICC line. There were scattered areas of desquamation on her chest and upper extremities. She was treated with broad-spectrum antimicrobials including clindamycin but her clinical status remained unchanged after 12 hours. It was decided to start methylprednisone for a possible adverse reaction to Avelumab. Given the concern for cytokine release syndrome, she was also given a single dose of Tocilizumab 800mg. Her condition improved dramatically in the next 24 hours; she was transferred out of the ICU on Day 3 of hospitalization and discharged home on Day 7 with a prednisone taper. On a follow-up appointment, her therapy was changed to an alkylating agent. Discussion: We present a case of CRS induced by Avelumab which resulted in rapid improvement of the rash and hemodynamic status of the patient after Tociluzimab. Our differential diagnosis included septic shock, including toxic shock syndrome. These circumstances are likely to be encountered by clinicians who are not primarily practicing in oncology.CRS is a systemic inflammatory disease characterized by a massive release of cytokines. By increasing the activity of the immune system against cancer cells and subsequently the host’s non-cancer cells, ICIs can lead to cytokine-mediated toxicity among which IL-6 plays a key role. CRS has now also been recognized to occur with ICIs, especially PD1 and PDL1 inhibitors. To our best knowledge, seven case reports have described CRS after pembrolizumab and nivolumab; however, none have specifically described this reaction to Avelumab. Rash was described in two case reports. Notably, our case is the only one that an ICI was used for an ependymal tumor. Two of the case reports described using tocilizumab and two used Mycophenolate. Corticosteroids were used in all cases and all patients recovered. Due to the increasing use of ICIs, more clinicians need to be aware that they can trigger CRS.